Markets

Why Gilead Sciences Stock Is on the Move Today

What happened

Shares of the biotech heavyweight Gilead Sciences (NASDAQ: GILD) are poised for a strong showing today. In pre-market trading, the company's stock jumped by as much as 7.2% Friday morning.

The catalyst? Gilead's stock is trending higher today in response to the full approval of its coronavirus treatment Veklury (remdesivir) by the Food and Drug Administration for hospitalized patients age 12 or older. The drug was previously given emergency use authorization by the FDA for a portion of this same patient population back in May.

3D rendering of the novel coronavirus.

Image source: Getty Images.

So what

Veklury should turn out to be a particularly important new growth product for the biotech for perhaps the next year or so -- that is, until the eventual mass distribution of an approved COVID-19 vaccine and/or another therapeutic such as a monoclonal antibody.

Underscoring this point, Gilead's $21 billion acquisition of Immunomedics isn't expected to contribute to the biotech's top line in a meaningful way for at least another two years. And its high-dollar collaboration with Belgian drugmaker Galapagos ran into a major stumbling block earlier this year with the surprise rejection of the rheumatoid arthritis medication filgotinib. In short, Gilead got a much-needed win with the full approval of Veklury for hospitalized COVID-19 patients.

Now what

Is Gilead's stock a buy on this positive regulatory news? That's hard to say. Veklury's commercial shelf life is likely to be short-lived. But this large-cap biotech stock is currently trading at a rather attractive 9.1 times forward-looking earnings, and this COVID-19 therapy may be the perfect bridge for Gilead's ongoing transition to an oncology-centric biopharma company. Buying the biotech's shares in the wake of this news, though, does require a degree of faith that its recent business development moves will ultimately pan out.

10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of October 20, 2020

George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Immunomedics. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD GLPG

Latest Markets Videos

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More